Back to top
more

Charles River Laboratories International (CRL)

(Delayed Data from NYSE)

$295.10 USD

295.10
1,231,097

-2.54 (-0.85%)

Updated Aug 26, 2026 04:00 PM ET

After-Market: $295.07 -0.03 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 247)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Unveiling Charles River (CRL) Q4 Outlook: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Zacks Equity Research

Charles River (CRL) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

The service business within Charles River (CRL) RMS is expected to have witnessed growth in the fourth quarter, banking on small molecule revenue increase across several geographic regions.

Zacks Equity Research

Charles River (CRL) Launches Animal-Free Endotoxin Test

by Zacks Equity Research

Charles River's (CRL) latest launch expands on Charles River's existing Trillium rCR vial product.

Zacks Equity Research

Charles River's (CRL) New Launch to Boost Gene Therapy Programs

by Zacks Equity Research

Charles River's (CRL) latest offering is likely to complete a comprehensive range of off-the-shelf plasmid products and simplify gene therapy supply chains with immediate availability.

Zacks Equity Research

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Investors are optimistic about Charles River (CRL) owing to growth in the RMS and DSA segments and stable solvency position.

Zacks Equity Research

Charles River's (CRL) Memphis Site Achieves Crucial Approval

by Zacks Equity Research

Charles River (CRL) reaches an important milestone in cell therapy manufacturing collaboration with Vertex Pharmaceuticals.

Zacks Equity Research

Charles River (CRL) Expands 3D In Vitro Services Via New Deal

by Zacks Equity Research

Charles River (CRL) finalizes agreement with service-based biotechnology company, CELLphenomics.

Zacks Equity Research

Charles River (CRL) Up 19.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Charles River's (CRL) share price is likely to grow, backed by the strength of the DSA segment.

Zacks Equity Research

Charles River (CRL) Gains on Price & Volume Growth Amid FX Woe

by Zacks Equity Research

At present, Charles River (CRL) is the largest provider of outsourced drug discovery, non-clinical development and regulated safety testing services worldwide.